Risdiplam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Risdiplam: From Spinal Muscular Atrophy (SMA) to Acne
One-Sentence Summary
Risdiplam is a small-molecule SMN2 pre-mRNA splicing modifier used to treat spinal muscular atrophy (SMA). The TxGNN model predicts it may be effective for Acne, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph similarity signal with no independent biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file in this evidence pack (drug not yet EU-marketed); based on known information, used for spinal muscular atrophy (SMA) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data for risdiplam is not available in this evidence pack. Based on known information, risdiplam is an SMN2 pre-mRNA splicing modifier — it increases production of functional SMN protein and is approved for spinal muscular atrophy (SMA), a neuromuscular disease driven by SMN protein deficiency.
Acne, by contrast, is a disease of sebaceous gland inflammation and androgen-driven sebum overproduction with follicular hyperkeratinization. There is no established biological pathway connecting SMN2 splicing modulation to sebaceous gland activity, androgen signaling, or acne pathophysiology. The evidence pack’s own rationale flags this explicitly: the prediction reflects TxGNN knowledge-graph embedding similarity rather than a supported mechanistic hypothesis.
It is also worth noting that several other top-10 predictions for this drug (e.g., multiple melanoma subtypes — metastatic, non-cutaneous, epithelioid cell, eyelid) cluster together without independent trial or literature support, which is a pattern often seen when embedding-space proximity drives predictions rather than genuine shared biology. This reinforces that the acne prediction should be treated as an early-stage, unvalidated hypothesis rather than a repurposing signal ready for clinical consideration.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Risdiplam is currently not marketed in the EU under this evidence pack (0 authorizations on file), so no product/indication table can be generated.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: key warnings, contraindications, and drug interaction data are currently unavailable — this is flagged as a Blocking data gap (DG001) that must be resolved before any safety-relevant decision can be made.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate sits at Evidence Level L5 (model prediction only, zero clinical trials or literature) with no plausible mechanistic link between SMN2 splicing modulation and acne pathophysiology. Combined with a Blocking data gap on safety warnings/contraindications, there is currently no basis to advance this candidate beyond S0.
To proceed, the following is needed:
- Confirmed original MOA and indication data for risdiplam (DG002 – High priority)
- TFDA/EMA label warnings and contraindications (DG001 – Blocking; required before any S1 safety screen)
- An independent mechanistic hypothesis linking SMN2/RNA splicing to sebaceous gland biology or acne pathogenesis
- At minimum, preclinical or case-level literature evidence before this candidate can be re-scored above L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.